CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more
Market Cap & Net Worth: CureVac NV (CVAC)
CureVac NV (NASDAQ:CVAC) has a market capitalization of $1.05 Billion ($1.05 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8011 globally and #4132 in its home market, demonstrating a 8.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CureVac NV's stock price $4.66 by its total outstanding shares 225172749 (225.17 Million).
CureVac NV Market Cap History: 2020 to 2026
CureVac NV's market capitalization history from 2020 to 2026. Data shows change from $18.25 Billion to $1.05 Billion (-36.89% CAGR).
Index Memberships
CureVac NV is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.04% | #222 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #879 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.05% | #136 of 263 |
Weight: CureVac NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CureVac NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CureVac NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.43x
CureVac NV's market cap is 1.43 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
4.73x
CureVac NV's market cap is 4.73 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $18.25 Billion | $48.90 Million | -$129.07 Million | 373.31x | N/A |
| 2021 | $7.73 Billion | $102.99 Million | -$411.72 Million | 75.01x | N/A |
| 2022 | $1.36 Billion | $67.42 Million | -$249.03 Million | 20.14x | N/A |
| 2023 | $947.98 Million | $53.76 Million | -$260.17 Million | 17.63x | N/A |
| 2024 | $767.84 Million | $535.18 Million | $162.19 Million | 1.43x | 4.73x |
Competitor Companies of CVAC by Market Capitalization
Companies near CureVac NV in the global market cap rankings as of March 18, 2026.
Key companies related to CureVac NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CureVac NV Historical Marketcap From 2020 to 2026
Between 2020 and today, CureVac NV's market cap moved from $18.25 Billion to $ 1.05 Billion, with a yearly change of -36.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.05 Billion | +3.10% |
| 2025 | $1.02 Billion | +32.55% |
| 2024 | $767.84 Million | -19.00% |
| 2023 | $947.98 Million | -30.18% |
| 2022 | $1.36 Billion | -82.42% |
| 2021 | $7.73 Billion | -57.68% |
| 2020 | $18.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CureVac NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.05 Billion USD |
| MoneyControl | $1.05 Billion USD |
| MarketWatch | $1.05 Billion USD |
| marketcap.company | $1.05 Billion USD |
| Reuters | $1.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.